Clinical Trial Update: A First In Human Study Of PF-00184562 In Healthy Volunteers [Phase 1]

View source ↗

Summary

Pfizer completed a first-in-human Phase 1 study of PF-00184562 in healthy volunteers to evaluate safety, tolerability and pharmacokinetics, with schizophrenia l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-00184562

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED